Research presented at the European League Against Rheumatism’s Annual European Congress of Rheumatology concluded that patients’ attitudes and level of satisfaction with switching to a biosimilar for etanercept or infliximab was associated with their level of health literacy, defined as being given sufficient and necessary information concerning their health.
Researchers found that 80% of patients taking originator etanercept (Enbrel) or originator infliximab (Remicade) who were switched to less expensive biosimilars reported being satisfied or neutral about being switched to a less expensive biosimilar medication. Nearly 1 in 5 patients reported being dissatisfied with the switch to a biosimilar medication. The researchers said that the patients’ attitudes and level of satisfaction with the biosimilar switch were associated with their level of health literacy, defined by the researchers as being given sufficient and necessary information concerning their health.
The study’s findings were presented by Milada Cvancarova Smastuen, PhD, and colleagues at the European League Against Rheumatism’s Annual European Congress of Rheumatology, held June 13-16, 2018, in Amsterdam.
Of the 290 Norwegian patients in the original study group taking Enbrel and Remicade, 155 reported being switched to a biosimilar. Only 14% of switched patients reported being involved in the decision to switch to a biosimilar. The researchers noted that economically motivated switching to biosimilar medications from originator biological medications has been in practice in Norway since 2016.
Data on patients’ attitudes toward, and experiences with, biosimilar switching were gathered from several questionnaires administered via a web survey in January 2017, which also collected demographic information such as gender, age, and marital status. Patients’ health-related literacy was measured using the Health Literacy Questionnaire, a multidimensional validated questionnaire. The investigators used 3 domains covering patients’ ability to actively engage with healthcare providers (scale 6), ability to find good health information (scale 8), and understanding health information well enough to know what to do (scale 9). Data were analyzed using multiple logistic regression and results were expressed as odds for being satisfied with the switch.
The authors found that self-assessed good health was strongly associated with a higher probability of being satisfied with the switch; only 9 of 74 patients who reported poor health also reported being satisfied. Adjusted for age and health self-assessment, scales 6 and 8 (but not 9) were significantly associated with higher odds of being satisfied with being switched (odds ration [OR], 2.5; 95% CI, 1.2-5.2 and OR, 2.7; 95% CI, 1.2-5.9, respectively).
The study also observed that:
Pfizer financially supported the study through an unrestricted grant.
Reference
Smastuen MC, Brandvold M, Andenaes R. Is patient satisfaction with being switched to a biosimilar medication associated with their level of health literacy? Results from a Norwegian user survey. Ann Rheum Dis. 2018;77(Suppl 2):86.
FTC Releases Second Report on PBMs Meddling in Generic Drug Markets
January 19th 2025The 3 largest pharmacy benefit managers (PBMs) increased many specialty generic drugs prices by hundreds of percent, with some drugs seeing thousands of percent markups, according to the Federal Trade Commission (FTC)’s second interim report on PBM practices.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Biosimilars Drive Cost Savings and Achieve 53% Market Share Across Treatment Areas
January 16th 2025Biosimilar launches achieve a 53% market share and a 53% reduction in average drug costs after 5 years of biosimilar competition, according to Samsung Bioepis’ most recent market report, showcasing notable pricing trends and market share disparities across therapeutic areas.
Improving Biosimilar Access Through Global Regulatory Convergence
January 15th 2025Achieving global regulatory harmonization for biosimilar vaccines and immunotherapies is essential to improving market access, reducing costs, and enhancing patient outcomes by streamlining approval processes, fostering international collaboration, and addressing regulatory disparities.
Cost-Efficiency in Action: Denmark's Transition to Biosimilar Adalimumab
January 14th 2025The nationwide mandatory switch from Humira (reference adalimumab) to biosimilar adalimumab in Denmark led to no increase in total health care costs over 9 months, with significant cost reductions for those who switched to GP2017 specifically, highlighting the economic feasibility of biosimilar adoption.